Short Interest in Immunic, Inc. (NASDAQ:IMUX) Increases By 14.9%

Immunic, Inc. (NASDAQ:IMUX) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 5,640,000 shares, an increase of 14.9% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 976,100 shares, the short-interest ratio is currently 5.8 days.

Analyst Ratings Changes

Several brokerages recently weighed in on IMUX. HC Wainwright began coverage on shares of Immunic in a research note on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock. D. Boral Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research note on Tuesday, January 7th. Finally, StockNews.com raised shares of Immunic from a “sell” rating to a “hold” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $12.67.

Insider Buying and Selling at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction dated Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently made changes to their positions in IMUX. HB Wealth Management LLC acquired a new position in shares of Immunic during the fourth quarter valued at about $81,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. Jane Street Group LLC lifted its position in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares in the last quarter. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at about $50,000. Finally, State Street Corp lifted its position in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Trading Down 3.9 %

Shares of IMUX opened at $0.98 on Monday. The stock has a market capitalization of $88.28 million, a P/E ratio of -0.80 and a beta of 1.88. The firm’s fifty day simple moving average is $1.09 and its two-hundred day simple moving average is $1.30. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). During the same quarter last year, the company earned ($0.51) EPS. As a group, research analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.